OR WAIT null SECS
Expansion expected to double batch capacity
Asymchem Laboratories, a contract development and manufacturing organization (CDMO) based in Tianjin, China, has completed construction of a new building at its Dunhua, China, production site. The expansion will add nearly 5,382 square feet of batch capacity to meet demands for upcoming commercialization projects. Further an active pharmaceutical ingredient (API) building expansion was completed at the company’s Tianjin site, with an expected new batch capacity of about 1,722 square feet.
“To meet the rapidly growing demand of Asymchem’s clients and projects, we have accelerated the construction of several small molecule R&D and production sites across China,” comments Chen Chaoyong, executive vice president of manufacturing at Asymchem. “By the end of 2022, we plan to have added 1,700 cubic meters [18,299 square feet] of small molecule batch capacity in Dunhua, Tianjin, and Yangtze River Delta, doubling existing batch capacity.”
Additionally, Asymchem plans to continue to increase the application of continuous flow technology in all of its sites. This includes upgrading several current modules and buildings and adding continuous flow equipment in new facilities. On the domestic front, the CDMO also acquired Snapdragon Chemistry, a Massachusetts-based chemical technology company, this past February.